A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, multi-dose escalation and dose expansion study in
subjects with selected advanced solid tumors (Part A), advanced recurrent immune checkpoint
refractory non-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer
(Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In
Part C of the study nab-paclitaxel will be administered subsequent to CM24 and nivolumab.